CYP2B66, CYP2B618, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe

201577 citationsJournal Articlegold Open Access

Authors

Milcah Dhoro · African Institute of Biomedical Science and Technology

Simbarashe Zvada · Stellenbosch University

Bernard Ngara · African Institute of Biomedical Science and Technology

Charles F. B. Nhachi · University of Zimbabwe

Gerald Kadzirange · University of Zimbabwe

Prosper Chonzi

Collen Masimirembwa · African Institute of Biomedical Science and Technology

Abstract

This study showed that screening for CYP2B6 functional variants has a high predictability for efavirenz plasma levels and could be used in prescribing optimal and safe EFV doses.

Topics & Keywords

HIV/AIDS drug development and treatment HIV Research and Treatment Pneumocystis jirovecii pneumonia detection and treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: BMC Pharmacology and Toxicology

Volume 16, Issue 1, pp. 4-4

DOI: 10.1186/s40360-015-0004-2

Field-Weighted Citation Impact: 6.21

Command Palette